Goldman Sachs Upgrades iQIYI to Buy, Announces $10 Price Target
Goldman Sachs analyst Lincoln Kong upgrades iQIYI (NASDAQ:IQ) from Neutral to Buy and announces $10 price target.
IQIYI Raises $600M Via Convertible Senior Note Offering For Debt Repayment
IQIYI, Inc (NASDAQ:IQ) raised $600 million via a secondary offering of 6.50% convertible senior notes due 2028. The notes will…
iQIYI To Raise $600M Via Convertible Senior Note Offering For Debt Repayment
iQIYI, Inc. (Nasdaq: IQ) ("iQIYI" or the "Company"), a leading provider of online entertainment video services in China, today announced the commencement of an offering by the
10 Communication Services Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Earnings Scheduled For February 22, 2023
Companies Reporting Before The Bell
• Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.
iQIYI Q4 Adj EPS $0.14 Beats $0.02 Estimate, Sales $1.10B Beat $1.09B Estimate
iQIYI (NASDAQ:IQ) reported adjusted quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.02 by 600 percent. This is a 140 percent increase over losses of $(0.35) per share from the same
MGM Resorts, Madison Square Garden Entertainment, Cardiovascular Systems And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Thursday. Here are some big stocks recording losses in today’s session.
What’s Going On With Dada Nexus And iQIYI Shares
Dada Nexus Ltd - ADR (NASDAQ: DADA) and iQIYI Inc - ADR (NASDAQ: IQ) shares are trading higher Friday afternoon.
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program CYAD-211.